Novo Nordisk A/S to respond to demand for the drugs Wegovy and Ozempic. Private Equity partners Matt Mauney and Andrew Kimball, and M&A partners Josh Zachariah, Kirkie Maswoswe, and Rachel Frankeny are advising Novo Nordisk’s largest shareholder, Novo Holdings. The deal comes as producers juggle to keep up with increasing demand for diabetes and obesity drugs Wegovy and Ozempic. The acquisition is intended to increase Novo Nordisk’s capacity. The deal is expected to close near the end of the year, subject to regulatory and shareholder approvals, the firms said. More in Bloomberg Law.